Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 2Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 1397Neoplasms 1129Prostatic Neoplasms 744Lung Neoplasms 619Colorectal Neoplasms 596Carcinoma, Non-Small-Cell Lung 569Carcinoma, Hepatocellular 413Pancreatic Neoplasms 402Leukemia, Myeloid, Acute 398Stomach Neoplasms 355Multiple Myeloma 326Brain Neoplasms 311Ovarian Neoplasms 309Head and Neck Neoplasms 289Neoplasm Metastasis 273Precursor Cell Lymphoblastic Leukemia-Lymphoma 260Rectal Neoplasms 253Uterine Cervical Neoplasms 248Recurrence 248Melanoma 242Esophageal Neoplasms 237Glioblastoma 232Squamous Cell Carcinoma of Head and Neck 231Lymphoma 213Sarcoma 207Urinary Bladder Neoplasms 192Colonic Neoplasms 192Glioma 191Triple Negative Breast Neoplasms 188Hematologic Neoplasms 183

Interventions

trifluridine tipiracil drug combination 1tipiracil 1irinotecan sucrosofate 1Trifluridine 1Ramucirumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × OTHER × Metastatic Gastric Adenocarcinoma × Clear all
NCT05927857 2026-04-09

Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .

National Health Research Institutes, Taiwan

Phase 1/2 Recruiting
45 enrolled
Gastrointestinal

Metastatic Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡